Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines
暂无分享,去创建一个
S. Ishikawa | H. Aburatani | Yusuke Nakamura | T. Niki | K. Miyazawa | M. Fukayama | A. Goto | D. Matsubara | S. Ota | O. Sachiko
[1] Yusuke Nakamura,et al. c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis , 2007, Cancer science.
[2] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[3] S. Ishikawa,et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway , 2007, Cancer science.
[4] W. Pao,et al. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[5] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[6] Gayatry Mohapatra,et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[7] S. Ishikawa,et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes , 2005, Cancer science.
[8] S. Hirohashi,et al. Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features , 2005, Clinical Cancer Research.
[9] Hiroyuki Aburatani,et al. Allelic dosage analysis with genotyping microarrays. , 2005, Biochemical and biophysical research communications.
[10] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[11] Ravi Salgia,et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.
[12] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[13] K. Miyazawa,et al. Activation of c‐Met (hepatocyte growth factor receptor) in human gastric cancer tissue , 2004, Cancer science.
[14] R. Kramer,et al. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. , 2004, The American journal of pathology.
[15] H. Kawamata,et al. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. , 2004, The American journal of pathology.
[16] L. Schmidt,et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.
[17] Douglas R Lowy,et al. E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases , 2004, The EMBO journal.
[18] R. Haba,et al. The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.
[19] J. Christensen,et al. c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.
[20] R. Salgia,et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.
[21] S. Hirohashi,et al. Cell adhesion system and human cancer morphogenesis , 2003, Cancer science.
[22] Miyuki Saito,et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. , 2002, The American journal of pathology.
[23] L. Ferrell,et al. Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.
[24] P. Leung,et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? , 2001, Oncogene.
[25] J. Coebergh,et al. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. , 2001, Lung cancer.
[26] M. Tsao,et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. , 1998, Lung cancer.
[27] H. Asamura,et al. Implications of staging in lung cancer. , 1997, Chest.
[28] S. Ōmura,et al. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.
[29] T. Yamamoto,et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. , 1996, Oncology.
[30] J. Bishop,et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Hirohashi,et al. Human Lung Cancer Cell Line Producing Hepatocyte Growth Factor/Scatter Factor , 1992, Japanese journal of cancer research : Gann.
[32] H. Tsubouchi,et al. The presence of scatter factor in patients with metastatic spread to the pleura. , 1992, British Journal of Cancer.
[33] G. Michalopoulos,et al. Hepatocyte growth factor , 1992, Hepatology.
[34] L. Naldini,et al. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. , 1991, The Journal of biological chemistry.
[35] S. Hirohashi,et al. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. , 1989, Cancer research.
[36] W. Jiang,et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. , 2005, Critical reviews in oncology/hematology.
[37] R. Salgia,et al. Role of receptor tyrosine kinases in lung cancer. , 2003, Methods in molecular medicine.
[38] B. Elliott,et al. Constitutive activation of met kinase in non‐small‐cell lung carcinomas correlates with anchorage‐independent cell survival , 2002, Journal of cellular biochemistry.
[39] W. Severs,et al. Subject Index, Vol. 53, 1996 , 1996 .